DEF 14A: Verastem, Inc. to Hold Annual Stockholders Meeting on May 23, 2024; Proposes Director Elections and Amended Equity Incentive Plan

Verastem, Inc. will hold its annual stockholders meeting on May 23, 2024, to vote on director elections, an amended equity incentive plan, and other corporate matters.

Summary

• Verastem, Inc. is holding its 2024 Annual Meeting of Stockholders on May 23, 2024, at 9:00 a.m. Eastern Time.
• Stockholders of record as of March 26, 2024, are entitled to vote.
• The meeting will address the election of four Class III directors (Paul Bunn, Anil Kapur, Daniel Paterson, and Michelle Robertson), approval of the Amended and Restated 2021 Equity Incentive Plan, ratification of Ernst & Young LLP as the independent registered public accounting firm, an advisory vote on executive compensation, and an advisory vote on the frequency of future executive compensation votes.
• The Board of Directors recommends voting for the election of the director nominees, for the approval of the Amended and Restated 2021 Equity Incentive Plan, for the ratification of Ernst & Young LLP, for the approval of the advisory vote on executive compensation and in favor of the one-year option on the frequency of future advisory votes on the compensation of our named executive officers.
• The company has engaged Alliance Advisors, LLC to assist in the solicitation of proxies, proxy related advice and information support for a fee of $12,500 plus reasonable out of pocket expenses.
• The Amended and Restated 2021 Equity Incentive Plan includes an increase of 3,200,000 shares available for issuance.
• The Board of Directors believes that the ability to grant equity compensation to all employees and directors has been, and will continue to be, essential to the Company’s ability to attract and retain the highest quality and highest performing employees and directors.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a slightly positive tone due to the Board's recommendations and belief in the benefits of the proposed equity plan.

Positives

• The Board of Directors believes that the ability to grant equity compensation to all employees and directors has been, and will continue to be, essential to the Company’s ability to attract and retain the highest quality and highest performing employees and directors.
• The Board of Directors believes that the Amended and Restated 2021 Plan will promote the interests of our stockholders and is consistent with principles of good corporate governance.

Risks

• The proxy materials contain forward-looking statements that are subject to risks and uncertainties, and actual results may differ materially.
• The company is dependent on the success of its research and development programs.

Future Outlook

The proxy materials contain forward-looking statements regarding the company's strategies, ability to attract and retain executives, and expectations for stockholder support of Board recommendations.

Management Comments

• The Board of Directors believes that equity awards have been, and will continue to be, a critical part of our total compensation program and allow us to attract and retain the key talent needed to effectively compete in our industry, incentivize superior results and long-term value creation, and align the interests of our employees with those of our stockholders.
• In addition, we believe that equity ownership fosters an ownership mindset by allowing employees to take part in the successes of the Company.

Industry Context

The document does not explicitly discuss industry context, but the discussion of executive compensation and equity incentive plans is standard practice for publicly traded companies in the biopharmaceutical industry.

Comparison to Industry Standards

• The Compensation Committee used peer group compensation data provided by Pearl Meyer, its independent compensation consultant, as a reference point in setting pay levels for executives for fiscal year 2023.
• These peers were chosen primarily based on selection criteria, as defined by the Compensation Committee.
• In the selection process, the Compensation Committee sought to develop a group that reflected Verastem's then current and projected near-term state by blending companies (i) in clinical stage development, (ii) with an employee workforce between 20 and 200 employees as of the last fiscal year end and (iii) with less than $200 million of operating expenses.
• We then selected companies which had market capitalizations between approximately $250,000,000 and $2,000,000,000.
• During the peer selection process, preference was given to Massachusetts-based companies, companies pursuing oncology indication or rare disease companies, and companies in Phase II or Phase III of clinical development.
• The Compensation Committee determined that our peer group to be used for 2023 compensation comparisons and decisions would be as follows: Alaunos Therapeutics, Inc., Pieris Pharmaceuticals, Inc., Evelo Biosciences,Inc., Replimune Group, Inc., Forma Therapeutics Holdings, Inc., Rubius Therapeutics, Inc., ImmunoGen, Inc., Scholar Rock Holding Corporation, Jounce Therapeutics, Inc., Seres Therapeutics, Inc., Kura Oncology, Inc., Surface Oncology, Inc., Leap Therapeutics, Inc., Syndax Pharmaceuticals, Inc., MEI Pharma, Inc., Syros Pharmaceuticals, Inc., Mersana Therapeutics, Inc.

Stakeholder Impact

• Approval of the Amended and Restated 2021 Equity Incentive Plan is intended to benefit stockholders by aligning employee and director interests with long-term value creation.
• The advisory vote on executive compensation allows stockholders to express their views on the company's pay practices.

Next Steps

• Stockholders are urged to vote their shares by internet, telephone, or mail.
• The Board of Directors will review and consider the voting results when making future decisions regarding executive compensation and related programs.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Equity Incentive Plan, Executive Compensation, Director Elections, Verastem